<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732212</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-013-07F</org_study_id>
    <nct_id>NCT00732212</nct_id>
  </id_info>
  <brief_title>Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage</brief_title>
  <official_title>Doppler Ultrasound Probe for Blood Flow Detection in Severe UGI Bleed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCLA Ronald Reagan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of this study are to compare clinical outcomes of two groups of patients
      with similar medical conditions (one with non-variceal upper gastrointestinal (UGI) lesions
      such as ulcers and another group with varices or portal hypertensive lesions) who are treated
      either with current standard visually guided endoscopic treatment according to stigmata of
      hemorrhage or with endoscopic Doppler endoscopic ultrasound probe (DEP) monitoring of blood
      flow in the lesion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: For patients with severe upper gastrointestinal (UGI) hemorrhage, risk
      stratification for rebleeding or endoscopic hemostasis has been based on visually defined
      endoscopic stigmata of hemorrhage for more than 40 years. These are imperfect, because there
      is significant interobserver variation and the investigators were previously unable to detect
      underlying vessel blood flow, which is directly related to the risk of rebleeding. Doppler
      ultrasound endoscopic probes (DEP) are relatively new in the US and can detect underlying
      lesion blood flow. However, few patients with severe UGI hemorrhage have been studied with
      endoscopic doppler ultrasound probe in the US and none in VA's. The Center for Ulcer Research
      and Education (CURE)/VA GI Hemostasis Research Group will perform prospective randomized
      studies at the West Los Angeles VA and University of California Los Angeles (UCLA) Ronald
      Reagan Medical Centers to define the role of DEP in management of severe UGI hemorrhage.

      Objectives: The specific aims (SA) of this research are: #1) In a randomized, blinded
      prospective controlled (RCT) study of patients with severe UGI hemorrhage (from
      varices/portal hypertensive lesions as one separate group vs. ulcers, &amp; other benign
      non-variceal sources as another group) to compare 30 day outcomes of patients in these 2
      major disease groups, managed by current standards (according to endoscopic visualization &amp;
      stigmata of hemorrhage) with similar patients assessed, risk stratified, &amp; treated with DEP
      monitoring. #2). For patients randomized to the DEP group, to determine the initial
      prevalence, type (arterial or venous), &amp; location &amp; course of blood flow underlying stigmata
      for the different lesion groups. #3). For DEP patients with different lesion types, to
      determine the rates of persistent blood flow after endoscopic hemostasis treatments &amp; whether
      blood flow after under stigmata can be eliminated by further endoscopic hemostasis with
      different techniques. #4). To determine the proportion of patients whose risk stratification
      (for rebleeding) &amp;/or endoscopic treatment are changed by utilizing DEP for detection of
      blood flow under stigmata of hemorrhage or lesions before as a guide for endoscopic treatment
      &amp; absence of flow after treatment as a treatment endpoint rather than visual guidelines
      (stigmata) alone for endoscopic treatment. #5). To compare the outcomes for a large cohort of
      historical controls previously treated for hemostasis of the two lesion types in the UGI
      tract by the CURE/VA Hemostasis Research Group according to visual guidelines &amp; stigmata
      alone with patients in the RCT managed with DEP findings &amp; stigmata, contrasting
      demographics, hemostasis rates, rebleeding rates &amp; other outcomes up to 30 days for major
      diagnoses (ulcers and other non-variceal lesions vs varices &amp; other lesions related to portal
      hypertension). #6). For patients who are treated with surgery or angiography for continued
      bleeding or rebleeding of UGI lesions, to correlate &amp; compare their vessel depth &amp; location
      (relative to stigmata), type of vessel, &amp; lumen patency at surgery or angiography vs. Doppler
      endoscopic probe findings recorded previously. Research Plan and Methods: All studies will be
      performed over 5 years. The investigators will utilize a large RCT (blinded), a very large
      cohort study, &amp; prospective observational studies to complete the specific aims of the study.
      Statistical Analysis System (SAS) will be utilized for data management. For SA #1, about 240
      new patients (150 with non-variceal lesions and 90 with variceal-portal hypertensive lesions)
      admitted to West Los Angeles (WLA) VA or UCLA Hospitals with severe UGI hemorrhage will be
      randomized in RCT of Doppler assisted management versus standard endoscopic/medical
      diagnosis, risk stratification, &amp; treatment. During urgent endoscopy, patients with clean
      varices (as the source of bleeding) or other UGI lesions with stigmata of recent hemorrhage
      (from the ulcers, Mallory Weiss tears, esophageal or gastric varices, and Dieulafoy's
      lesions) will be randomized. Routine clinical outcomes will be assessed prospectively &amp;
      compared by major diagnostic groups (ulcers-non-variceal lesions or varices-portal
      hypertensive lesions). For SA #5 (UGI cohort study), demographics, outcomes, &amp; risk factors
      will be compared for about 150 patients with non-variceal lesions &amp; about 90 other
      variceal-portal hypertensive lesion matched historical control patients (from CURE Hemostasis
      Research Databases) treated previously only based upon stigmata vs. 75 new patients with
      non-variceal UGI lesions or 50 variceal-portal hypertension lesions in this study treated
      according to stigmata of hemorrhage &amp; DEP as a guide to risk stratification &amp; endoscopic
      hemostasis. SA #2-4 &amp; 6 will be prospectively performed according to the methods in the
      proposal &amp; all analysis will be performed with the collaboration of an experienced
      biostatistician.

      Potential Impact on Veterans and Non- VA Healthcare: These studies will increase our
      knowledge about UGI bleeding, UGI lesion vasculature, blood flow, and effects of endoscopic
      hemostasis. Also, DEP may improve risk stratification of Veteran patients, medical and
      endoscopic management &amp; outcomes of patients with severe UGI hemorrhage from different
      etiologies. This is particularly relevant to patient care of Veterans with severe UGI
      hemorrhage, since this is a common clinical condition which requires considerable health care
      resources in every VA hospital. These results will also be generalizable to non-VA hospitals
      and the US population who is hospitalized with severe UGI bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2009</start_date>
  <completion_date type="Actual">January 7, 2016</completion_date>
  <primary_completion_date type="Actual">January 7, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 Day Rebleeding Rate</measure>
    <time_frame>30 days</time_frame>
    <description>The primary outcome is index lesion rebleeding rate up to 30 days in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Surgery up to 30 Days After Randomization</measure>
    <time_frame>30 days</time_frame>
    <description>GI surgery rate for control of active bleeding or rebleeding - up to 30 days after randomization in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Rates for each treatment group will be determined and compared for General medical complications (pneumonia, infection, myocardial infarction, stroke) &amp; GI procedure related (perforation, aspiration) up to 30 days in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days</time_frame>
    <description>Death up to 30 days from a co-morbid condition, bleeding, or another cause in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Units of Red Blood Cells (RBC) Transfused for Rebleeding After Randomization</measure>
    <time_frame>30 days</time_frame>
    <description>RBC units of transfusion post-randomization will be quantitated &amp; compared in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospital Days After Randomization</measure>
    <time_frame>30 days</time_frame>
    <description>Comparisons of days spent in the ICU and hospital will be quantitated &amp; compared in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">235</enrollment>
  <condition>UGI Bleeding</condition>
  <condition>Ulcer or Variceal Hemorrhage</condition>
  <condition>Stigmata of Recent Hemorrhage</condition>
  <condition>Endoscopy</condition>
  <condition>Randomized Controlled Trials</condition>
  <arm_group>
    <arm_group_label>Doppler endoscopic probe hemostasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Endoscopic Hemostasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Doppler endoscopic ultrasound probe for blood flow detection</intervention_name>
    <description>Used for blood flow detection</description>
    <arm_group_label>Doppler endoscopic probe hemostasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard endoscopic hemostasis</intervention_name>
    <description>Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage &amp; visual cues for risk stratification and completion of endoscopic treatment.</description>
    <arm_group_label>Standard Endoscopic Hemostasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have evidence of severe UGI bleeding by laboratory tests (Hgb less than
             or equal to 9 gms; with red blood cell (RBC) transfusions; or documented decrease in
             Hgb of greater than or equal to 2 gms relative to baseline) and by clinical parameters
             (melena; hematemesis or hematochezia; nasogastric tube (NG) evidence of UGI bleeding-
             fresh blood, clots, or old blood).

          -  The following non-variceal UGI lesions will be included if stigmata of hemorrhage are
             found on emergency endoscopy (active arterial bleeding, oozing, non-bleeding visible
             vessel (NBVV), adherent clot, or flat spot or a combination of these) for peptic
             ulcers (gastric, duodenal, esophageal, or anastomatic), Mallory-Weiss (MW) tears
             without portal hypertension (PHTN), or Dieulafoy's lesions.

          -  For other types of severe UGI bleeding related to PHTN, the investigators will include
             patients with esophageal or gastric varices (with or without stigmata, if no other UGI
             lesion is the source of the bleed); post-rubber band ligation (RBL) ulcers, and MW
             tears associated with PHTN and having some stigmata of recent hemorrhage.

          -  Life expectancy of at least 60 days based on lack of very severe or terminal
             comorbidity, as judged by the generalists or specialists caring for the patient.

          -  Written informed consent by patient or surrogate.

        Exclusion Criteria:

          -  Patients who are uncooperative, unable to give written informed consent, who cannot
             return for 30 day follow-up, or refuse informed consent.

          -  Patients with UGI known malignancies or malignant appearing ulcers; diffuse bleeding
             from mucosal lesions or esophagitis; infectious UGI lesions; or other bleeding lesions
             (polyps, post-endoscopic mucosal resection (EMR), or post-sphincterotomy).

          -  End-stage, very severe, recurrent or ongoing co-morbid illness, e.g. severe liver,
             renal, cardiac, respiratory failure; peritonitis; or sepsis that preclude emergency
             procedures or clinical follow-up and limit survival.

          -  Persistent shock or hypotension (e.g. systolic blood pressure less than or equal to 99
             mm mercury) that is unresponsive to less than or equal to 6 units of packed red blood
             cell (RBC) transfusions or requires continuous intravenous infusions of vasoactive
             drugs for blood pressure elevation.

          -  Severe coagulopathy unresponsive to blood transfusions e.g. international normalized
             ratio (INR) &gt; 2.0, platelet count &lt; 20,000, activated partial thromboplastin time
             (APTT) greater than 2.0 x normal, or bleeding time &gt; 10 minutes.

          -  Contraindication to urgent endoscopy or follow-up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis M. Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles Healthcare System, West Los Angeles, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System, West Los Angeles, CA</name>
      <address>
        <city>West Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <results_first_submitted>February 24, 2017</results_first_submitted>
  <results_first_submitted_qc>February 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2017</results_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UGI Bleeding</keyword>
  <keyword>Ulcer or variceal hemorrhage</keyword>
  <keyword>Stigmata of recent hemorrhage</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Non-variceal UGI hemorrhage</keyword>
  <keyword>Variceal hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Doppler Endoscopic Probe Assisted Hemostasis</title>
          <description>In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.
Doppler endoscopic ultrasound probe is used for blood flow detection</description>
        </group>
        <group group_id="P2">
          <title>Standard Endoscopic Hemostasis</title>
          <description>Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines
Standard endoscopic hemostasis: Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage &amp; visual cues for risk stratification and completion of endoscopic treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Temporarily Suspended</title>
              <participants_list>
                <participants group_id="P1" count="50">Study was suspended for a 9 month period by the VA DMC because of slow enrollment, then restarted.</participants>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Non-variceal Group</title>
          <description>Standard non-variceal treatment patient characteristics, risk factors and the primary outcome (rebleed with 30 days) were analyzed. Each specified variable and 30 day lesion rebleeding were compared between the two treatment groups separately by time period using the Chi-Square or Fisher exact tests (for categorical variables) or the Wilcoxon rank sum test (for continuous variables).</description>
        </group>
        <group group_id="B2">
          <title>Doppler Non-variceal Group</title>
          <description>Doppler non-variceal treatment patient characteristics, risk factors and the primary outcome (rebleed with 30 days) were analyzed. Each specified variable and 30 day lesion rebleeding were compared between the two treatment groups separately by time period using the Chi-Square or Fisher exact tests (for categorical variables) or the Wilcoxon rank sum test (for continuous variables).</description>
        </group>
        <group group_id="B3">
          <title>Standard Variceal Group</title>
          <description>Standard variceal treatment patient characteristics, risk factors and the primary outcome (rebleed with 30 days) were analyzed. Each specified variable and 30 day lesion rebleeding were compared between the two treatment groups separately by time period using the Chi-Square or Fisher exact tests (for categorical variables) or the Wilcoxon rank sum test (for continuous variables).</description>
        </group>
        <group group_id="B4">
          <title>Doppler Variceal Group</title>
          <description>Doppler variceal treatment patient characteristics, risk factors and the primary outcome (rebleed with 30 days) were analyzed. Each specified variable and 30 day lesion rebleeding were compared between the two treatment groups separately by time period using the Chi-Square or Fisher exact tests (for categorical variables) or the Wilcoxon rank sum test (for continuous variables).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="235"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="16.1"/>
                    <measurement group_id="B2" value="65" spread="15.6"/>
                    <measurement group_id="B3" value="57.1" spread="9.8"/>
                    <measurement group_id="B4" value="54.7" spread="11.7"/>
                    <measurement group_id="B5" value="60.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>30 Day Rebleeding Rate</title>
        <description>The primary outcome is index lesion rebleeding rate up to 30 days in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Non-variceal Group</title>
            <description>30 day rebleeding rate in standard non-variceal visually guided hemostasis patients.</description>
          </group>
          <group group_id="O2">
            <title>Doppler Non-variceal Group</title>
            <description>30 day rebleeding rate in Doppler assisted non-variceal patients.</description>
          </group>
          <group group_id="O3">
            <title>Standard Variceal Group</title>
            <description>30 day rebleeding rate in standard variceal visually guided hemostasis patients.</description>
          </group>
          <group group_id="O4">
            <title>Doppler Variceal Group</title>
            <description>30 day rebleeding rate in Doppler assisted variceal patients.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day Rebleeding Rate</title>
          <description>The primary outcome is index lesion rebleeding rate up to 30 days in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Surgery up to 30 Days After Randomization</title>
        <description>GI surgery rate for control of active bleeding or rebleeding - up to 30 days after randomization in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Non-variceal Group</title>
            <description>30 day rate of surgery in standard visually guided hemostasis non-variceal patients.</description>
          </group>
          <group group_id="O2">
            <title>Doppler Non-variceal Group</title>
            <description>30 day rate of surgery in Doppler assisted non-variceal patients.</description>
          </group>
          <group group_id="O3">
            <title>Standard Variceal Group</title>
            <description>30 day rate of surgery in standard visually guided hemostasis variceal patients.</description>
          </group>
          <group group_id="O4">
            <title>Doppler Variceal Group</title>
            <description>30 day rate of surgery in Doppler assisted variceal patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Surgery up to 30 Days After Randomization</title>
          <description>GI surgery rate for control of active bleeding or rebleeding - up to 30 days after randomization in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complications</title>
        <description>Rates for each treatment group will be determined and compared for General medical complications (pneumonia, infection, myocardial infarction, stroke) &amp; GI procedure related (perforation, aspiration) up to 30 days in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Non-variceal Group</title>
            <description>Rate of standard visually guided hemostasis non-variceal patients who had complications within 30 days.</description>
          </group>
          <group group_id="O2">
            <title>Doppler Non-variceal Group</title>
            <description>Rate of Doppler assisted non-variceal patients who had complications within 30 days.</description>
          </group>
          <group group_id="O3">
            <title>Standard Variceal Group</title>
            <description>Rate of standard visually guided hemostasis variceal patients who had complications within 30 days.</description>
          </group>
          <group group_id="O4">
            <title>Doppler Variceal Patients</title>
            <description>Rate of Doppler assisted variceal patients who had complications within 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complications</title>
          <description>Rates for each treatment group will be determined and compared for General medical complications (pneumonia, infection, myocardial infarction, stroke) &amp; GI procedure related (perforation, aspiration) up to 30 days in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>Death up to 30 days from a co-morbid condition, bleeding, or another cause in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Non-variceal Group</title>
            <description>Number of deaths in standard visually guided hemostasis non-variceal patients within 30 days from a co-morbid condition, bleeding, or another cause.</description>
          </group>
          <group group_id="O2">
            <title>Doppler Non-variceal Group</title>
            <description>Number of deaths in Doppler assisted non-variceal patients within 30 days from a co-morbid condition, bleeding, or another cause.</description>
          </group>
          <group group_id="O3">
            <title>Standard Variceal Group</title>
            <description>Number of deaths in standard visually guided hemostasis variceal patients within 30 days from a co-morbid condition, bleeding, or another cause.</description>
          </group>
          <group group_id="O4">
            <title>Doppler Variceal Group</title>
            <description>Number of deaths in Doppler assisted variceal patients within 30 days from a co-morbid condition, bleeding, or another cause.</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Death up to 30 days from a co-morbid condition, bleeding, or another cause in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Units of Red Blood Cells (RBC) Transfused for Rebleeding After Randomization</title>
        <description>RBC units of transfusion post-randomization will be quantitated &amp; compared in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Non-variceal Group</title>
            <description>RBC units of transfusion post-randomization in standard visually guided hemostasis non-variceal patients.</description>
          </group>
          <group group_id="O2">
            <title>Doppler Non-variceal Group</title>
            <description>RBC units of transfusion post-randomization in Doppler assisted non-variceal patients.</description>
          </group>
          <group group_id="O3">
            <title>Standard Variceal Group</title>
            <description>RBC units of transfusion post-randomization in standard visually guided hemostasis variceal patients.</description>
          </group>
          <group group_id="O4">
            <title>Doppler Variceal Group</title>
            <description>RBC units of transfusion post-randomization in Doppler assisted variceal patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Units of Red Blood Cells (RBC) Transfused for Rebleeding After Randomization</title>
          <description>RBC units of transfusion post-randomization will be quantitated &amp; compared in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
          <units>Units of RBC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="2.94"/>
                    <measurement group_id="O2" value="0.56" spread="2.41"/>
                    <measurement group_id="O3" value="2.00" spread="5.48"/>
                    <measurement group_id="O4" value="1.33" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospital Days After Randomization</title>
        <description>Comparisons of days spent in the ICU and hospital will be quantitated &amp; compared in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Non-variceal Group</title>
            <description>Length of hospitalization days in standard visually guided hemostasis non-variceal patients.</description>
          </group>
          <group group_id="O2">
            <title>Doppler Non-variceal Group</title>
            <description>Length of hospitalization days in Doppler assisted non-variceal patients.</description>
          </group>
          <group group_id="O3">
            <title>Standard Variceal Group</title>
            <description>Length of hospitalization days in standard visually guided hemostasis variceal patients.</description>
          </group>
          <group group_id="O4">
            <title>Doppler Variceal Group</title>
            <description>Length of hospitalization days in Doppler assisted variceal patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Days After Randomization</title>
          <description>Comparisons of days spent in the ICU and hospital will be quantitated &amp; compared in 2 subgroups- non-variceal or variceal-portal hypertension lesions according to standard visually guided hemostasis vs. Doppler assisted.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="8.79"/>
                    <measurement group_id="O2" value="6.65" spread="8.48"/>
                    <measurement group_id="O3" value="11.32" spread="10.55"/>
                    <measurement group_id="O4" value="7.18" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the start of the study until the completion of the study over a time period of 7 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Non-variceal Group</title>
          <description>Serious adverse events in standard non-variceal visually guided hemostasis patients.</description>
        </group>
        <group group_id="E2">
          <title>Doppler Non-variceal Group</title>
          <description>Serious adverse events in Doppler non-variceal patients.</description>
        </group>
        <group group_id="E3">
          <title>Standard Variceal Group</title>
          <description>Serious adverse events in standard variceal visually guided hemostasis patients.</description>
        </group>
        <group group_id="E4">
          <title>Doppler Variceal Group</title>
          <description>Serious adverse events in Doppler variceal visually guided hemostasis patients.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Potential limitations of this study are expense of equipment, learning curve as new technology, and no other randomized controlled studies have been reported to confirm the results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dennis M. Jensen, M.D.</name_or_title>
      <organization>CURE Digestive Diseases Research Center</organization>
      <phone>310-268-3569</phone>
      <email>djensen@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

